Low-grade Glioma

• EMA approval · 2026-02-27
  New medicine to treat paediatric low-grade glioma

  EMA approved a new medicine, Ojemda, to treat paediatric low-grade glioma in children aged 6 months and older, including tumours with BRAF a…

• CLINICAL_TRIALS approval · 2024-08-12
  Clinical Trial Update: Expanded Access Program (EAP) for Tovorafenib (DAY101) in RAF-Altered, Relapsed or Refractory Low-Grade Glioma

  Tovorafenib (DAY101) has been approved for marketing for RAF-altered, relapsed or refractory low-grade glioma, with an Expanded Access Progr…

• FDA approval · 2024-04-23
  FDA Approved: OJEMDA — Original Application (Day One Biopharmaceuticals, Inc.)

  FDA approved OJEMDA (tovorafenib) from Day One Biopharmaceuticals as a new drug for the treatment of patients with low-grade glioma.